- Home
- RYDE vs TENX Comparison
RYDE vs TENX Comparison
Compare RYDE & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYDE
- TENX
- Stock Information
- Founded
- RYDE 2014
- TENX 1967
- Country
- RYDE Singapore
- TENX United States
- Employees
- RYDE N/A
- TENX N/A
- Industry
- RYDE
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- RYDE
- TENX Health Care
- Exchange
- RYDE NYSE
- TENX Nasdaq
- Market Cap
- RYDE 5.2M
- TENX 21.6M
- IPO Year
- RYDE 2024
- TENX N/A
- Fundamental
- Price
- RYDE $0.32
- TENX $5.81
- Analyst Decision
- RYDE
- TENX Strong Buy
- Analyst Count
- RYDE 0
- TENX 3
- Target Price
- RYDE N/A
- TENX $16.00
- AVG Volume (30 Days)
- RYDE 29.3M
- TENX 42.1K
- Earning Date
- RYDE 05-02-2025
- TENX 08-12-2025
- Dividend Yield
- RYDE N/A
- TENX N/A
- EPS Growth
- RYDE N/A
- TENX N/A
- EPS
- RYDE N/A
- TENX N/A
- Revenue
- RYDE $6,557,978.00
- TENX N/A
- Revenue This Year
- RYDE $21.13
- TENX N/A
- Revenue Next Year
- RYDE $13.43
- TENX N/A
- P/E Ratio
- RYDE N/A
- TENX N/A
- Revenue Growth
- RYDE 3.27
- TENX N/A
- 52 Week Low
- RYDE $0.16
- TENX $2.80
- 52 Week High
- RYDE $22.49
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- RYDE N/A
- TENX 49.28
- Support Level
- RYDE N/A
- TENX $5.66
- Resistance Level
- RYDE N/A
- TENX $6.00
- Average True Range (ATR)
- RYDE 0.00
- TENX 0.53
- MACD
- RYDE 0.00
- TENX -0.01
- Stochastic Oscillator
- RYDE 0.00
- TENX 33.33
About RYDE RYDE GROUP LTD
Ryde Group Ltd operates a technology platform that provides a range of ride-hailing, carpooling and delivery focused offerings in Singapore. The company operates in twos segments namely Mobility provides on-demand and scheduled carpooling and ride-hailing services, matching riders to its driver partners; and Quick Commerce provides on-demand, scheduled, and multi-stop parcel delivery services.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.